The effects of denosumab on cortical bone parameters at the hip and their clinical relevance in women with postmenopausal osteoporosis aged <75 and ≥75 years

被引：0
|
作者：
Genant, H. K. [1 ,2 ]
Keaveny, T. M. [3 ,4 ]
Zapalowski, C. [5 ]
Engelke, K. [2 ]
Fuerst, T. [2 ]
Kendler, D. L. [6 ]
Recknor, C. [7 ]
Boonen, S. [8 ]
Wang, A. [5 ]
Dakin, P. [5 ]
Libanati, C. [5 ]
McClung, M. R. [9 ]
机构：
[1] USCF, San Francisco, CA USA
[2] Synarc Inc, San Francisco, CA USA
[3] Univ Calif Berkeley, Berkeley, CA USA
[4] ON Diagnost, Berkeley, CA USA
[5] Amgen Inc, Thousand Oaks, CA 91320 USA
[6] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[7] United Osteoporosis Ctr, Gainesville, GA USA
[8] Leuven Univ, Leuven, Belgium
[9] Oregon Osteoporosis Ctr, Portland, OR USA
来源：
AUSTRALASIAN JOURNAL ON AGEING | 2014年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
FP17
引用
收藏
页码：59 / 59
页数：1
相关论文
共 50 条
  • [21] Letter to the Editor: "Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis"
    Sugiyama, Toshihiro
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (07): : 2756 - 2757
  • [22] DENOSUMAB TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS FOR 7 YEARS: CLINICAL FRACTURE RESULTS FROM THE FIRST 4 YEARS OF THE FREEDOM EXTENSION
    Lippuner, Kurt
    Roux, C.
    Bone, H. G.
    Zapalowski, C.
    Minisola, S.
    Franek, E.
    Lakatos, P.
    Kendler, D.
    Lewiecki, E. M.
    Mautalen, C.
    Jensen, S.
    Wang, A.
    Daizadeh, N.
    Wagman, R. B.
    Boonen, S.
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 : S39 - S40
  • [23] DENOSUMAB TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS FOR 7 YEARS: CLINICAL FRACTURE RESULTS FROM THE FIRST 4 YEARS OF THE FREEDOM EXTENSION
    Roux, C.
    Lippuner, K.
    Bone, H. G.
    Zapalowski, C.
    Minisola, S.
    Franek, E.
    Lakatos, P.
    Kendler, D.
    Lewiecki, E. M.
    Mautalen, C.
    Jensen, S.
    Wang, A.
    Daizadeh, N.
    Wagman, R. B.
    Boonen, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 137 - 137
  • [24] Clinical Efficacy and Safety of Denosumab in Postmenopausal Women with Low Bone Mineral Density and Osteoporosis: A Meta-Analysis
    von Keyserlingk, Camilla
    Hopkins, Robert
    Anastasilakis, Athanasios
    Toulis, Konstantinos
    Goeree, Ron
    Tarride, Jean-Eric
    Xie, Feng
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2011, 41 (02) : 178 - 186
  • [25] Lifetime occupation and hip bone mineral status in men aged 60-75 years in Shenyang, China
    Yan, L
    Prentice, A
    Zhou, B
    Wang, X
    Wang, S
    Laskey, MA
    BONE, 2001, 28 (05) : S184 - S185
  • [26] WHOLE BODY AND REGIONAL BONE MINERAL CONTENT AND DENSITY IN WOMEN AGED 20-75 YEARS
    Boyanov, M. A.
    ACTA ENDOCRINOLOGICA-BUCHAREST, 2016, 12 (02) : 191 - 196
  • [27] Effects of up to 8 years of denosumab treatment in women with postmenopausal osteoporosis: Results: from the first 5 years of the FREEDOM extension
    Papapoulos, Socrates
    Lippuner, Kurt
    Roux, Christian
    Lin, Celia
    Kendler, David
    Lewiecki, E. Michael
    Brandi, Maria Luisa
    Czerwinski, Edward
    Franek, Edward
    Lakatos, Peter
    Mautalen, Carlos
    Minisola, Salvatore
    Reginster, Jean Yves
    Jensen, Soren
    Daizadeh, Nadia
    Wang, Andrea
    Gavin, Mary
    Wagman, Rachel B.
    Bone, Henry G.
    AUSTRALASIAN JOURNAL ON AGEING, 2014, 33 : 14 - 15
  • [28] EFFECTS OF ABALOPARATIDE-SC ON BONE MINERAL DENSITY AND RISK OF FRACTURE IN POSTMENOPAUSAL WOMEN AGED 80 YEARS OR OLDER WITH OSTEOPOROSIS
    McClung, M.
    Harvey, N. C.
    Fitzpatrick, L. A.
    Miller, P.
    Hattersley, G.
    Wang, Y.
    Cosman, F.
    OSTEOPOROSIS INTERNATIONAL, 2017, 28 : S407 - S407
  • [29] Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis
    Eastell, Richard
    Reid, David M.
    Vukicevic, Slobodan
    Ensrud, Kristine E.
    LaCroix, Andrea Z.
    Thompson, John R.
    Thompson, David D.
    Cummings, Steven R.
    BONE, 2012, 50 (05) : 1135 - 1140
  • [30] FIVE YEARS OF TREATMENT WITH RISEDRONATE AND ITS EFFECTS ON BONE SAFETY IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS
    Sod, E.
    Johnson, T. D.
    Chines, A.
    Melsen, F.
    CALCIFIED TISSUE INTERNATIONAL, 2004, 74 : S80 - S80
12345